Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis

Published:2016-08-18 Issue:1 Volume:31 Page:136-142
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Landau H,Smith M,Landry C,Chou J F,Devlin S M,Hassoun H,Bello C,Giralt S,Comenzo R L

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2016229.pdf

Reference31 articles.

1. Comenzo RL, Gertz MA. . Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276–4282.

2. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083–1093.

3. Landau H, Hassoun H, Rosenzweig MA, Maurer M, Liu J, Flombaum C et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 2013; 27: 823–828.

4. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011; 118: 4346–4352.

5. Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/– thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 2007; 139: 224–233.

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of AL amyloidosis in the era of novel immune and cellular therapies;Frontiers in Oncology;2024-06-28

2. Systemic Light Chain Amyloidosis;The EBMT Handbook;2024

3. Hematopoietic Cell Transplantation in Light Chain Amyloidosis;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

4. Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis;Cells;2023-12-18

5. Prediction models for major adverse cardiovascular events following ST-segment elevation myocardial infarction and subgroup-specific performance;Frontiers in Cardiovascular Medicine;2023-04-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3